TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 2611360

Group type: EXPERIMENTAL
Intervention: Flurbiprofen with Maalox (antacid)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Flurbiprofen every 12 h from Day 3 to Day 8 with Maalox (antacid)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Flurbiprofen without Maalox (antacid)
Number of subjects: 19
Study: 577520

Group type: EXPERIMENTAL
Intervention: Duck embryo rabies vaccine (DEV)
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Duck embryo rabies vaccine purified by ultracentrifugation (P-DEV)
Number of subjects: 92
Study: 31472438

Group type: EXPERIMENTAL
Intervention: Chemoradiation (CRT) using Aldestein RTOG regimen
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Induction chemotherapy followed by Cetuximab radiation (IBRT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Overall survival comparison
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Data collection quality
Number of subjects: 0
Study: 28282099

Group type: EXPERIMENTAL
Intervention: Angle-resolved Raman spectroscopy on TiS3, ZrS3, and HfS3
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Angle-resolved studies on TiNbS3 TMTC alloy
Number of subjects: 0
Study: 25805608

Group type: EXPERIMENTAL
Intervention: SFC 50/100 µg delivered via Rotacaps(®)/Rotahaler(®)
Number of subjects: 0

Group type: COMPARATOR
Intervention: SFC 50/100 µg delivered via Diskus(®)
Number of subjects: 0
Study: 24167545

Group type: EXPERIMENTAL
Intervention: Serum ferritin
Number of subjects: 423

Group type: EXPERIMENTAL
Intervention: Serum transferrin receptor (sTfR)
Number of subjects: 423

Group type: EXPERIMENTAL
Intervention: Adiponectin
Number of subjects: 423

Group type: EXPERIMENTAL
Intervention: Total and uncarboxylated osteocalcin
Number of subjects: 423
Study: 21415046

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioural therapy (CBT) with fluoxetine if indicated, 20 sessions over 18 weeks
Number of subjects: 293

Group type: COMPARATOR
Intervention: Stepped-care approach starting with supervised self-help, with fluoxetine added if non-responders after 6 sessions, followed by CBT if needed
Number of subjects: 293
Study: 19011153

Group type: EXPERIMENTAL
Intervention: Very Low Calorie Diet (VLCD) with supervised lifestyle counseling
Number of subjects: 72

Group type: COMPARATOR
Intervention: Routine lifestyle counseling
Number of subjects: 72
Study: 17398182

Group type: EXPERIMENTAL
Intervention: FilterWire EZ
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (regular guidewires)
Number of subjects: 100
Study: 14716714

Group type: EXPERIMENTAL
Intervention: Glucose (four 3 mg dextrose tablets)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Placebo (sorbitol tablets)
Number of subjects: 75
Study: 11511119

Group type: EXPERIMENTAL
Intervention: (18)F-fluoro-2-deoxyglucose (FDG) positron emission tomography during a standardized euglycaemic hyperinsulinaemic glucose clamp
Number of subjects: 178

Group type: EXPERIMENTAL
Intervention: Postoperative improvement in ejection fraction
Number of subjects: 178
Study: 9581743

Group type: EXPERIMENTAL
Intervention: Ibutilide (1 mg IV infusion, two 10-min infusions)
Number of subjects: 127

Group type: COMPARATOR
Intervention: Procainamide (400 mg IV infusion, three successive 10-min infusions)
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: Ibutilide (in atrial flutter subgroup)
Number of subjects: 127

Group type: COMPARATOR
Intervention: Procainamide (in atrial flutter subgroup)
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: Ibutilide (in atrial fibrillation subgroup)
Number of subjects: 127

Group type: COMPARATOR
Intervention: Procainamide (in atrial fibrillation subgroup)
Number of subjects: 127

Group type: COMPARATOR
Intervention: Procainamide
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: Ibutilide
Number of subjects: 127
Study: 9048272

Group type: EXPERIMENTAL
Intervention: Perindopril 2 mg/day
Number of subjects: 208

Group type: EXPERIMENTAL
Intervention: Perindopril 4 mg/day
Number of subjects: 208

Group type: EXPERIMENTAL
Intervention: Perindopril 8 mg/day
Number of subjects: 208

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 208

Group type: EXPERIMENTAL
Intervention: All treatment groups
Number of subjects: 208
Study: 1937372

Group type: EXPERIMENTAL
Intervention: Omeprazole (30 mg taken as a single morning dose)
Number of subjects: 143

Group type: COMPARATOR
Intervention: Ranitidine (400 mg b.i.d.)
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Omeprazole
Number of subjects: 143

Group type: COMPARATOR
Intervention: Ranitidine
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Both drugs
Number of subjects: 143
Study: 6310075

Group type: EXPERIMENTAL
Intervention: Mineral oil
Number of subjects: 37

Group type: COMPARATOR
Intervention: Senokot (standardized senna concentrate)
Number of subjects: 37
Study: 31937335

Group type: EXPERIMENTAL
Intervention: Compatible acupoints group
Number of subjects: 216

Group type: EXPERIMENTAL
Intervention: Single acupoint group
Number of subjects: 216

Group type: COMPARATOR
Intervention: Sham acupuncture group
Number of subjects: 216

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 216
Study: 31537697

Group type: EXPERIMENTAL
Intervention: 5 years surveillance with annual sputum samples for cytology and cytometry, followed by annual LDCT and autofluorescence bronchoscopy (AFB) if abnormal.
Number of subjects: 1568

Group type: COMPARATOR
Intervention: Not applicable (control group).
Number of subjects: 1568

Group type: EXPERIMENTAL
Intervention: Sputum cytology/cytometry.
Number of subjects: 1568

Group type: EXPERIMENTAL
Intervention: AFB for sputum-positive individuals.
Number of subjects: 1568

Group type: EXPERIMENTAL
Intervention: LDCT for sputum-positive individuals.
Number of subjects: 1568
Study: 27654637

Group type: EXPERIMENTAL
Intervention: TEAMS therapy
Number of subjects: 14
Study: 27882838

Group type: EXPERIMENTAL
Intervention: Enhanced Pharmacy Care (EPC)
Number of subjects: 1002

Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 1002
Study: 23785050

Group type: EXPERIMENTAL
Intervention: Enoxaparin 0.5 mg/kg bolus intravenously 10 to 15 minutes before procedure, followed by 40 mg once daily for 7 days in low-risk group.
Number of subjects: 184

Group type: EXPERIMENTAL
Intervention: Enoxaparin 0.5 mg/kg bolus intravenously 10 to 15 minutes before procedure, followed by 1 mg/kg subcutaneously 2 times a day for 48 hours, then 40 mg once daily for 5 days in high-risk group.
Number of subjects: 184
Study: 21899708

Group type: EXPERIMENTAL
Intervention: Vaseline (n = 49)
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: 2% lidocaine gel (n = 51)
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: 2.5% lidocaine plus 2.5% prilocaine cream (n = 46)
Number of subjects: 146
Study: 20169261

Group type: EXPERIMENTAL
Intervention: LTS-D (disposable laryngeal tube suction)
Number of subjects: 60

Group type: COMPARATOR
Intervention: LTS-II (reusable laryngeal tube suction)
Number of subjects: 60
Study: 18779616

Group type: EXPERIMENTAL
Intervention: Clodronate, 1.6 g orally administered daily
Number of subjects: 268

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 268
Study: 15721693

Group type: EXPERIMENTAL
Intervention: LASIK (n=25; mean SER -7.12 D ± 0.57 [SD])
Number of subjects: 45

Group type: COMPARATOR
Intervention: PRK (n=20; mean SER -6.91 ± 0.57 D)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: LASIK
Number of subjects: 45

Group type: COMPARATOR
Intervention: PRK
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: LASIK and PRK
Number of subjects: 45
Study: 12741452

Group type: EXPERIMENTAL
Intervention: Rabeprazole 20 mg daily for 4 weeks
Number of subjects: 223

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 223
Study: 10595816

Group type: EXPERIMENTAL
Intervention: Ondansetron
Number of subjects: 187

Group type: EXPERIMENTAL
Intervention: Granisetron
Number of subjects: 187

Group type: EXPERIMENTAL
Intervention: Total-body irradiation-containing conditioning regimens
Number of subjects: 187

Group type: EXPERIMENTAL
Intervention: Nausea scoring system
Number of subjects: 187
Study: 9373732

Group type: EXPERIMENTAL
Intervention: IFN alpha-2b (3 x 10(6) IU, 3 times weekly)
Number of subjects: 162
Study: 1399377

Group type: EXPERIMENTAL
Intervention: Aztreonam
Number of subjects: 55

Group type: COMPARATOR
Intervention: Gentamicin
Number of subjects: 55
Study: 2409356

Group type: EXPERIMENTAL
Intervention: Antihypertensive drugs
Number of subjects: 0

Group type: COMPARATOR
Intervention: Matched placebos
Number of subjects: 0
Study: 31455384

Group type: EXPERIMENTAL
Intervention: In-bed cycling intervention
Number of subjects: 256
Study: 29766635

Group type: EXPERIMENTAL
Intervention: MK-1293 insulin glargine (Mk-Gla; 100 U/mL)
Number of subjects: 508

Group type: COMPARATOR
Intervention: Originator insulin glargine (Lantus; Sa-Gla)
Number of subjects: 508

Group type: EXPERIMENTAL
Intervention: MK-1293 insulin glargine (Mk-Gla)
Number of subjects: 508

Group type: EXPERIMENTAL
Intervention: Both MK-1293 and Sa-Gla
Number of subjects: 508
Study: 27548031

Group type: EXPERIMENTAL
Intervention: Strengthening Families Program plus Life Skills Training (SFP 10‐14 + LST)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Life Skills Training (LST) only
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Cigarette frequency
Number of subjects: 36
Study: 24910399

Group type: EXPERIMENTAL
Intervention: Knee stabilization therapy prior to strength/functional training
Number of subjects: 159

Group type: COMPARATOR
Intervention: Control programme (without knee stabilization therapy)
Number of subjects: 159
Study: 21954229

Group type: EXPERIMENTAL
Intervention: WGET intervention group
Number of subjects: 417

Group type: EXPERIMENTAL
Intervention: VCRC-LS intervention group
Number of subjects: 417
Study: 19443132

Group type: EXPERIMENTAL
Intervention: Marijuana smoked as joints (0.0, 1.8, and 3.6% THC)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Marijuana smoked as blunts (0.0, 1.8, and 3.6% THC)
Number of subjects: 24
Study: 17160087

Group type: EXPERIMENTAL
Intervention: Intervention group (4 GP consultations over 12 weeks)
Number of subjects: 163

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 163
Study: 15580176

Group type: EXPERIMENTAL
Intervention: Primary caregivers
Number of subjects: 75

Group type: COMPARATOR
Intervention: Controls
Number of subjects: 75
Study: 11428474

Group type: EXPERIMENTAL
Intervention: Lone atrial fibrillation with embolic stroke
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Right hemispheric dominance
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Left hemispheric dominance
Number of subjects: 0
Study: 8288727

Group type: EXPERIMENTAL
Intervention: Lovastatin (20 mg bid)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study: 3553111

Group type: EXPERIMENTAL
Intervention: Postoperative radiotherapy (XRT) - 50 Gy in 20 fractions to the kidney bed and regional lymph nodes
Number of subjects: 65

Group type: COMPARATOR
Intervention: Observation (no further treatment)
Number of subjects: 65
Study: 30166301

Group type: EXPERIMENTAL
Intervention: Methylphenidate
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 27486878

Group type: EXPERIMENTAL
Intervention: TPF induction chemotherapy (docetaxel, cisplatin, and fluorouracil)
Number of subjects: 278

Group type: COMPARATOR
Intervention: PF induction chemotherapy (cisplatin and fluorouracil)
Number of subjects: 278

Group type: EXPERIMENTAL
Intervention: TPF induction chemotherapy
Number of subjects: 278

Group type: COMPARATOR
Intervention: PF induction chemotherapy
Number of subjects: 278
Study: 25602687

Group type: EXPERIMENTAL
Intervention: Oligonol (200 mg daily for 1 week)
Number of subjects: 20
Study: 24200273

Group type: EXPERIMENTAL
Intervention: Brochure-using group
Number of subjects: 100

Group type: COMPARATOR
Intervention: Non-using group
Number of subjects: 100
Study: 21167471

Group type: EXPERIMENTAL
Intervention: Tinidazole 500 mg twice daily
Number of subjects: 593

Group type: EXPERIMENTAL
Intervention: Tinidazole 1 g twice daily
Number of subjects: 593

Group type: COMPARATOR
Intervention: Metronidazole 500 mg twice daily
Number of subjects: 593
Study: 18482424

Group type: EXPERIMENTAL
Intervention: Contingent voucher condition
Number of subjects: 82

Group type: COMPARATOR
Intervention: Non-contingent voucher condition
Number of subjects: 82
Study: 16939849

Group type: EXPERIMENTAL
Intervention: Cancer inpatients
Number of subjects: 25
Study: 12883767

Group type: EXPERIMENTAL
Intervention: Open (Bankart)
Number of subjects: 147

Group type: COMPARATOR
Intervention: Arthroscopic (ASK)
Number of subjects: 147
Study: 11719823

Group type: EXPERIMENTAL
Intervention: Oral micronized estradiol substitution (Group I)
Number of subjects: 7500

Group type: COMPARATOR
Intervention: No estradiol substitution (Group II)
Number of subjects: 7500
Study: 9123736

Group type: EXPERIMENTAL
Intervention: 3 months of neoadjuvant androgen deprivation therapy (ADT) with 3.6 mg goserelin for 28 days and 750 mg flutamide daily
Number of subjects: 141

Group type: COMPARATOR
Intervention: Control group (no ADT prior to surgery)
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: 3 months of neoadjuvant ADT (goserelin and flutamide)
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Neoadjuvant ADT (goserelin and flutamide)
Number of subjects: 141

Group type: COMPARATOR
Intervention: Control group (surgery alone)
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: ADT-treated patients
Number of subjects: 141

Group type: COMPARATOR
Intervention: Control patients
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Neoadjuvant ADT
Number of subjects: 141
Study: 1362748

Group type: EXPERIMENTAL
Intervention: Amoxycillin-clavulanic acid
Number of subjects: 150

Group type: COMPARATOR
Intervention: Cefamandole
Number of subjects: 150
Study: 3423732

Group type: EXPERIMENTAL
Intervention: sucralfate
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: De‐Nol
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Maalox 70
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: sucralfate, De‐Nol, and Maalox 70
Number of subjects: 34

Group type: COMPARATOR
Intervention: atropine
Number of subjects: 34

Group type: COMPARATOR
Intervention: aspirin
Number of subjects: 34

Group type: COMPARATOR
Intervention: pirenzepine
Number of subjects: 34
Study: 30465070

Group type: EXPERIMENTAL
Intervention: Erythromycin
Number of subjects: 332

Group type: COMPARATOR
Intervention: Metoclopramide
Number of subjects: 332
Study: 27776246

Group type: EXPERIMENTAL
Intervention: Nicotine patch wear time during the first week post-quit
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Wearing the patch for ≥19h
Number of subjects: 74
Study: 26283275

Group type: EXPERIMENTAL
Intervention: Sitagliptin 100mg once daily
Number of subjects: 71

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 71
Study: 24035889

Group type: EXPERIMENTAL
Intervention: Complete free choice
Number of subjects: 288

Group type: EXPERIMENTAL
Intervention: Providing choice
Number of subjects: 288

Group type: COMPARATOR
Intervention: Explaining relevance
Number of subjects: 288
Study: 22269666

Group type: EXPERIMENTAL
Intervention: Localized 311-nm narrow-band ultraviolet B (NB-UVB)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: 308-nm monochromatic excimer light (MEL)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study: 19143914

Group type: EXPERIMENTAL
Intervention: Sildenafil treatment (flexible-dose or fixed-dose)
Number of subjects: 1296

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1296
Study: 16715674

Group type: EXPERIMENTAL
Intervention: 30 g iodine
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: 24 g iodine
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: 15 g iodine
Number of subjects: 66
Study: 14754790

Group type: EXPERIMENTAL
Intervention: Citalopram (10 mg)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 10
Study: 11395041

Group type: EXPERIMENTAL
Intervention: FH patients
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: FH patients with vascular disease
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: FH patients with and without vascular disease
Number of subjects: 51
Study: 9243654

Group type: EXPERIMENTAL
Intervention: Routine preoperative testing prior to cataract surgery
Number of subjects: 20000

Group type: COMPARATOR
Intervention: Exclusion of second eye surgeries
Number of subjects: 20000

Group type: EXPERIMENTAL
Intervention: Inclusion of first and second eyes but randomization of patients rather than eyes
Number of subjects: 20000

Group type: EXPERIMENTAL
Intervention: Inclusion of first and second eyes but randomization of surgeries rather than patients
Number of subjects: 20000
Study: 8299830

Group type: EXPERIMENTAL
Intervention: Computed radiography with a photostimulable storage phosphor (50% radiation dose)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Computed radiography with a photostimulable storage phosphor (20% radiation dose)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Computed radiography with a photostimulable storage phosphor (10% radiation dose)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Conventional calcium tungstate screen‐film combination (100% radiation dose)
Number of subjects: 40
Study: 3773621

Group type: EXPERIMENTAL
Intervention: Two-channel amplitude compression hearing aid
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Single-channel amplitude compression hearing aid
Number of subjects: 12

Group type: COMPARATOR
Intervention: Personal aid
Number of subjects: 12
Study: 31659595

Group type: EXPERIMENTAL
Intervention: Gluten-Free Diet (GFD)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Gluten-Containing Diet (GD)
Number of subjects: 66
Study: 29879606

Group type: EXPERIMENTAL
Intervention: Agomelatine 25-50mg
Number of subjects: 633

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 633
Study: 27559716

Group type: EXPERIMENTAL
Intervention: ω‐3 plus capsules
Number of subjects: 140

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 140
Study: 25266981

Group type: EXPERIMENTAL
Intervention: Bioabsorbable steroid-eluting implant with 1350 μg of mometasone furoate
Number of subjects: 100

Group type: COMPARATOR
Intervention: Sham procedure
Number of subjects: 100
Study: 23733326

Group type: EXPERIMENTAL
Intervention: Dynamic Constant External Resistance (DCER) training
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Isokinetic (ISOK) training
Number of subjects: 31

Group type: COMPARATOR
Intervention: Control (CONT) group
Number of subjects: 31
Study: 20077006

Group type: EXPERIMENTAL
Intervention: Assertive community treatment (ACT) with illness management and recovery (IMR)
Number of subjects: 183

Group type: COMPARATOR
Intervention: Assertive community treatment (ACT) without IMR
Number of subjects: 183
Study: 19202956

Group type: EXPERIMENTAL
Intervention: Long-acting β-agonists (LABAs) with inhaled corticosteroid (ICS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Long-acting β-agonists (LABAs) without inhaled corticosteroid (ICS)
Number of subjects: 0
Study: 16122670

Group type: EXPERIMENTAL
Intervention: Ultrasonic root-end preparation
Number of subjects: 50
Study: 12672582

Group type: EXPERIMENTAL
Intervention: Ceftriaxone (75 mg/kg per day, max 2 g/day, intravenously, in two doses until defervescence and continued 5 days after)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Chloramphenicol (75 mg/kg per day, max 2 g/day, in four doses for 14 days)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Ceftriaxone
Number of subjects: 72

Group type: COMPARATOR
Intervention: Chloramphenicol
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Ceftriaxone and Chloramphenicol
Number of subjects: 72
Study: 10230328

Group type: EXPERIMENTAL
Intervention: Propofol 2.5 mg/kg
Number of subjects: 165

Group type: COMPARATOR
Intervention: Etomidate 0.3 mg/kg
Number of subjects: 165

Group type: COMPARATOR
Intervention: Thiopentone 5 mg/kg
Number of subjects: 165
Study: 8721349

Group type: EXPERIMENTAL
Intervention: Sho‐Seiryu‐To extract
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sho‐Saiko‐To extract
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Licorice extract
Number of subjects: 0
Study: 1992843

Group type: EXPERIMENTAL
Intervention: Transdermally administered nicotine
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study: 6839667

Group type: EXPERIMENTAL
Intervention: Human milk
Number of subjects: 30

Group type: COMPARATOR
Intervention: Low-protein formula (casein)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Low-protein formula (whey)
Number of subjects: 30
Study: 31916033

Group type: EXPERIMENTAL
Intervention: Immediate implant placement with immediate provisionalization (TG)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control group (CG) with immediate implants with intact alveoli
Number of subjects: 12
Study: 30945798

Group type: EXPERIMENTAL
Intervention: Single-coil leads (SC-leads)
Number of subjects: 2475

Group type: EXPERIMENTAL
Intervention: Dual-coil leads (DC-leads)
Number of subjects: 2475
Study: 28388294

Group type: EXPERIMENTAL
Intervention: Bizzy Diet + FitMiss Burn (BURN)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Bizzy Diet + Placebo (PLA)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 39
Study: 26808384

Group type: EXPERIMENTAL
Intervention: Extended Depth of Focus lenses (EDOF)
Number of subjects: 41
Study: 24552382

Group type: EXPERIMENTAL
Intervention: JUICE (freeze-dried fruit and vegetable juice powder)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Control (nonJUICE)
Number of subjects: 34
Study: 22623016

Group type: EXPERIMENTAL
Intervention: Tramadol (350 mg)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Hydromorphone (16 mg)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Naltrexone (50 mg)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 19509107

Group type: EXPERIMENTAL
Intervention: Recombinant human TSH injections (0.9 mg im per 2 consecutive days) - group B
Number of subjects: 20

Group type: COMPARATOR
Intervention: Levothyroxine withdrawal (30 days) - group A
Number of subjects: 20
Study: 16870661

Group type: EXPERIMENTAL
Intervention: GSTM1 null genotype
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: GSTP1 Valine/Valine genotype
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Both GSTM1 null and GSTP1 Val/Val genotypes
Number of subjects: 151

Group type: COMPARATOR
Intervention: GSTP1 genotypes
Number of subjects: 151
Study: 15747762

Group type: EXPERIMENTAL
Intervention: Early retinal ablative treatment
Number of subjects: 317

Group type: COMPARATOR
Intervention: Conventional management (control eye)
Number of subjects: 317